TD Waterhouse Canada Inc. Sells 3,271 Shares of Stryker Corporation $SYK

TD Waterhouse Canada Inc. decreased its holdings in Stryker Corporation (NYSE:SYK) by 1.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 210,670 shares of the medical technology company’s stock after selling 3,271 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Stryker were worth $66,002,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. Sankala Group LLC purchased a new stake in shares of Stryker in the 4th quarter worth about $26,000. Godfrey Financial Associates Inc. purchased a new position in shares of Stryker during the fourth quarter valued at about $26,000. United Financial Planning Group LLC bought a new position in Stryker in the third quarter worth about $27,000. Atlas Capital Advisors Inc. purchased a new stake in Stryker in the fourth quarter worth about $27,000. Finally, Gables Capital Management Inc. purchased a new stake in Stryker in the second quarter worth about $25,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on SYK. Citigroup reiterated a “buy” rating on shares of Stryker in a report on Thursday, August 13th. Leerink Partners lowered their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. BMO Capital Markets assumed coverage on Stryker in a research report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price target on the stock. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Argus set a $370.00 price objective on Stryker in a report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $386.28.

Insiders Place Their Bets

In other news, Director Ronda Stryker sold 50,000 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the sale, the director directly owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Debra King sold 826 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is currently owned by corporate insiders.

Stryker Price Performance

Shares of SYK opened at $308.07 on Friday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The firm’s 50-day simple moving average is $329.43 and its two-hundred day simple moving average is $329.92. The stock has a market cap of $118.17 billion, a PE ratio of 31.92, a price-to-earnings-growth ratio of 1.95 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same period last year, the business earned $3.13 earnings per share. The business’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts anticipate that Stryker Corporation will post 15.03 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is presently 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.